Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.720,81
1,32%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Plus Therapeutics Inc (PSTV) Plus Therapeutics Inc (PSTV) Notizie

Plus Therapeutics Inc

PSTV
1,80
0,00 (0,00%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/4/202413:00GLOBEPlus Therapeutics Receives $3 Million Award Recommendation..
08/3/202422:30EDGAR2Form S-1/A - General form for registration of securities..
05/3/202422:04EDGAR2Form 8-K - Current report
05/3/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202400:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202322:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202322:08EDGAR2Form S-1 - General form for registration of securities under..
21/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
20/11/202313:01EDGAR2Form 8-K - Current report
17/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202321:55EDGAR2Form 8-K - Current report
31/10/202321:06EDGAR2Form 8-K - Current report
31/10/202321:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/9/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202313:00GLOBEPlus Therapeutics Receives $1.9 Million Advance Payment from..
08/9/202313:00GLOBEPlus Therapeutics Enters into License Agreement for..
05/9/202313:00GLOBEPlus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a..
30/8/202313:00GLOBEPlus Therapeutics to Present at the H.C. Wainwright 25th..
21/8/202312:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:12EDGAR2Form 8-K - Current report
14/8/202322:05GLOBEPlus Therapeutics Reports Second Quarter 2023 Financial..
14/8/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202312:30GLOBEPlus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at..
09/8/202313:55EDGAR2Form S-1 - General form for registration of securities under..
08/8/202322:05GLOBEPlus Therapeutics to Announce Second Quarter 2023 Financial..
08/8/202317:22GLOBEPlus Therapeutics Announces Key Opinion Leader Roundtable on..
03/8/202313:00GLOBEPlus Therapeutics to Present at the Canaccord Genuity 43rd..
27/7/202322:05GLOBEPlus Therapeutics Strengthens Clinical Program with the..
27/7/202313:00GLOBEPlus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer..
13/7/202313:00GLOBEPlus Therapeutics to Present at the 2nd Annual Targeted..
29/6/202313:00GLOBEPlus Therapeutics Reports Positive Interim Updates from Two..
14/6/202313:00GLOBEPlus Therapeutics to Participate in the 2023 Healthcare..
08/6/202313:00GLOBEPlus Therapeutics Announces Participation at Upcoming SNO..
01/6/202313:00GLOBEPlus Therapeutics Provides Company Update Today
30/5/202313:00GLOBEPlus Therapeutics Announces Topline Results from Recurrent..
25/5/202313:00GLOBEPlus Therapeutics to Present at the 2023 Virtual June..
16/5/202313:00GLOBEPlus Therapeutics Regains Compliance with Nasdaq Listing..
12/5/202313:00GLOBEPlus Therapeutics to Present in EndBrainCancer Initiative..
Apertura: 1,80 Min: 1,80 Max: 1,84
Chiusura: 1,80

La tua Cronologia

NASDAQ
PSTV
Plus Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network